Biotherapic T. cruzi 17DH when continuously used clinically improves mice infected with T. cruzi

• Published in: International journal of high dilution research Vol. 10; no. 36; pp. 134 - 137
• Main Authors: Aleixo, Denise Lessa, Ferreira, Érika Cristina Ferreira Cristina Ferreira, Braga, Caroline Felicio, Lopes, Carina Ribeiro, Falkowski, Gislaine Janaina Sanchez, Sandri, Patricia Flora, Araujo, Silvana Marques de
• Format: Journal Article
• Language: English
• Published: 23-12-2021
• ISSN: 1982-6206; 1982-6206
• DOI: 10.51910/ijhdr.v10i36.478

Introduction: In Trypanosoma cruzi infection, the pathogenesis is the result of a rupture in the host - parasite relationship [1]. This rupture is related to the imbalance of the vital force of the host, expressed through signs and symptoms, defined by Hahnemann (1995)[2] as being the source of the disease. There is no research in the literature about the clinical evolution of mice experimentally infected with T. cruzi and treated in different ways using biotherapic. Therefore, this is an area to be studied in the future.
Aim: To evaluate the effect of different ways of treatment using biotherapic T. cruzi 17 DH on clinical evolution of mice experimentally infected with T. cruzi.
Materials and methods: A blind randomized controlled trial was performed, using 30 swiss male mice, aged 28 days, divided into groups according to the treatment: CONTROL - animals treated with 7% water-alcohol solution diluted in water given ad libitum in an amber bottle; GAVAGE – animals treated with medication highly diluted T. cruzi 17 DH from 4th to 9th day of infection by gavage; WATER -animals treated with highly diluted T. cruzi 17 DH in water ad libitum offered in an amber bottle until the end of the study period. The groups were infected with the Y strain of T. cruzi, intraperitoneal, 1400 blood trypomastigotes. The medicine was handled according to the Brazilian Homeopathic Pharmacopoeia [3] with microbiological test according to RDC n° 67 and in vivo biological risk. Parasitemic curve was determined by daily counting of the parasites [4]. Were measured temperature, weight, intake of water and feed, the ruffle fur and survival of mice. Statistical analysis was performed using the tests Fisher Exact and Log-Rank, with a significance of 5%. The experiment was approved under the protocol n° 030/2008 - Ethics in Animal Experimentation of the Universidade Estadual de Maringá.
Results: The mice under different treatment ways using biotherapic T. cruzi 17DH showed differences in the clinical evolution. The treatment using biotherapic diluted in water initially shows hypothermia, with subsequent recovery of normal temperature (p=0.05) (Fig1). The weight curve shows a better evolution in mice treated with water compared to control groups (p=0.055) and the groups treated by gavage (p=0.0064). Feed and water intake did not differ among the groups. While the mice that were treated with biotherapic diluted in water showed a slight level of ruffled fur, the mice in control groups and the ones treated by gavage showed a more intense level of ruffled fur (p=0.00001). The difference in the evolution of mortality among the groups was significant (p=0.034), while in the group treated with biotherapic diluted with water, the mortality rate started later, reaching the maximum of 90%. This group showed a better clinical result, expressed by the smaller extent of ruffled fur, a better evolution of the temperature curve and higher gain of weight. This is an important result because the Y strain of T. cruzi has a mortality rate of 100% in mice, showing once again the good performance of biotherapic in this model of infection.
Conclusion: The use of biotherapic T. cruzi 17DH for a long period causes clinical improvement of the infected mice with Trypanosoma cruzi. The clinical use of these results in human beings should consider the allometric medicine dosage which takes into account the metabolic rate of each organism.